Previous 10 | Next 10 |
2023-10-18 00:04:36 ET Summary Tyvaso DPI, a collaboration with United Therapeutics, diversifies MannKind's revenue streams and leverages its proprietary Technosphere technology, bolstering long-term prospects. While Afrezza faces challenges like pricing and reimbursement, MNKD's ...
2023-10-10 14:44:04 ET More on MannKind MannKind's Robust Patient Demand, Operational Efficiency To Drive Revenue Beyond Q2 2023 MannKind Corporation 2023 Q2 - Results - Earnings Call Presentation MannKind Corporation (MNKD) Q2 2023 Earnings Call Transcript S...
2023-09-07 07:08:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharma stocks can be a great way to add profits to your investment account. Companies that make lifesaving medications or develop treatments to ease symptoms can be true moneymakers. Finding th...
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today th...
2023-08-14 12:44:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors who’ve dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure i...
2023-08-08 17:16:41 ET Commercial-stage biotech MannKind (NASDAQ: MNKD) was a top choice of investors on the second day of the trading week. Tuesday saw MannKind's share price leap by almost 19%, making it stand out on a day when the S&P 500 index slumped by 0.4%. The re...
2023-08-08 11:29:33 ET Summary MannKind Corporation beats analysts on earnings and revenue in Q2 2023, with a year-over-year increase of 157.3% in revenue. Strong demand for Afrezza and Tyvaso DPI contributes to revenue growth. The company aims to reach profitability in its En...
2023-08-08 01:09:05 ET MannKind Corporation (MNKD) Q2 2023 Earnings Conference Call August 7, 2023 17:00 ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Chief Financial Officer Conference Call Participants Steven Lichtman...
2023-08-08 00:00:23 ET Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q2 2023 Earnings Call Aug 07, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: MannKind (MNKD) Q2 2023 Earnings Call Transcript
2023-08-07 16:04:22 ET MannKind press release ( NASDAQ: MNKD ): Q2 Non-GAAP EPS of $0.00 beats by $0.04 . Revenue of $48.61M (+157.3% Y/Y) beats by $5.66M . 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17%...
17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck ...